508 Background: The Office of High Cost of the Colombian Health Ministry created the National Administrative Cancer Registry (NACR) in 2015 to obtain nationwide cancer data to find areas for improvement in cancer delivery. From initial data, a collaboration of healthcare experts identified 15 disease management indicators in colorectal (CRC) cancer in Colombia. In this study, we look at 2017 NACR data to investigate significant findings. Methods: We obtained NACR data compiled from the Department of Health Ministry from January 2, 2016-January 1, 2017 consisting of 32 departments and 1122 municipalities. The 2017 NACR data for CRC includes 11 of 15 updated disease management indicators - time to diagnosis, proportion of patients with colorectal cancer in situ, proportion of new cases identified in early stages, proportion of patients with TNM staging, proportion of patients with TNM staging before treatment, time before treatment, time between neoadjuvant therapy and surgery, time between surgery and adjuvant therapy, proportion of stage I and II patients receiving curative surgery, proportion of patients with nutritional support, mortality rate, and incidence. Results: The incidence of CRC was 5.2 cases per 100,000 people and the mortality was 3.6 cases per 100,000 people. The time to diagnosis was on average 50.7 days. 3.6% of CRC cases were in situ. 35.6% of cases were identified in early stages, and 51.3% of cases had TNM staging with 45.1% staged prior to treatment. The time to initial treatment was 63.7 days. The time between neoadjuvant therapy and surgery was 116.1 days and the time between surgery and adjuvant therapy was 75.5 days. 24.2% of stage I and II patients received curative surgery. 9.8% patients received nutritional support. Conclusions: The updated NACR data show significant wait times for treatment and exaggerated wait times for patients needing neoadjuvant or adjuvant therapies. The findings show significant work is needed in providing supportive services. There needs to be further investigation into follow-up after initial treatment. Further directions should include more data collection of adjuvant and neoadjuvant wait times and outcomes data of specific treatment modalities.